

PERNIX THERAPEUTICS HOLDINGS, INC. TO REPORT THIRD QUARTER 2015 FINANCIAL RESULTS ON THURSDAY, NOVEMBER 5, 2015

October 22, 2015 2:03 PM ET

MORRISTOWN, NJ – October 22, 2015 – Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that it will release its 2015 third quarter financial results on Thursday, November 5, 2015, before the market opens.

Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date: Thursday, November 5, 2015

Time: 8:30 A.M. EST

Toll free (U.S.): 877-312-8783

International: 408-940-3874

Webcast (live and replay): <http://www.pernixtx.com/investors/webcasts-presentations>

The presentation will be webcast and available on the Investors section of the Company's website at <http://www.pernixtx.com/investors/webcasts-presentations/>. A replay of the webcast will be available for 30 days after the date of the presentation.

About Pernix Therapeutics

Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.

To learn more about Pernix Therapeutics, visit www.pernixtx.com.

Pernix Therapeutics Holdings, Inc.

Investor Relations

Sanjay Patel, (800) 793-2145 ext. 1009

Chief Financial Officer

spatel@pernixtx.com

Lisa Wilson, (212) 452-2793

In-Site Communications, Inc.

lwilson@insitecony.com

Media Relations

Marianne Lambertson, (800) 793-2145 ext. 1012

Vice President, Strategic Development

mlambertson@pernixtx.com